Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
24,013.20
(
-0.01%
)
Dow Jones
46,946.41
(
0.00%
)
Brent Oil
99.99
(
1.71%
)
Bitcoin
73,862.05
(
-1.32%
)
News Focus
News Focus
Post# of 80490
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: biotech_researcher post# 47616

Saturday, 03/08/2014 6:47:17 PM

Saturday, March 08, 2014 6:47:17 PM

Post# of 80490
>> For comparison, CLVS is an early stage biotech, with compounds in phase I trials and sports a $3 billion market cap.

Maybe you should update your information on CLVS. CLVS has three drug candidates: Rucaparib is in ph3 registration trial for ovarian cancer; Lucitanib in ph2 trial for FGFR+ breast cancer; CO1686 in ph1 expansion trial, with registration trial coming up shortly for EGFR+T790M NSCLC.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now